Hyderabad: Indian Immunologicals Ltd, a city-based facility below the National Dairy Development Board, has introduced its plans to start the production of drug substance meant for COVID-19 vaccine Covaxin from June 15, and despatch the primary batch to Bharat Biotech by July.
IILs Managing Director Okay Anand Kumar in a launch on Friday mentioned the agency is anticipated to produce the drug substance initially for 2-3 million doses per 30 days.
It will probably be scaled up to 7 million later within the yr and ultimately to 15 million.
To additional improve the COVID-19 vaccine manufacturing capability, Bharat Biotech had mentioned it partnered with IIL to make the drug substance for Covaxin.
The know-how switch course of was effectively underway and IIL has the capabilities and experience to manufacture inactivated viral vaccines at business scale and below biosafety containment, the drug had mentioned.
Kumar mentioned IIL is changing its Karkapatla manufacturing unit close to right here right into a Biosafety Level -3 (BSL3) facility for the production of the drug substance and likewise taking over building of one other block.
IIL can also be engaged on one other COVID -19 vaccine and the animal trials are underway and is anticipated to come out subsequent yr for human vaccination, he famous.